Re-PERFUSE: Phase 1b Study of AZD3427, a Novel Relaxin Receptor Agonist, on Renal Perfusion in HFrEF Patients
This study, alongside other ongoing AZD3427 studies, aims to evaluate the dual effects of AZD3427 in improving both cardiac and renal function. These insights could guide the development of future therapeutic strategies for managing HF and renal impairment.
Authors
- Andrea Varrone (ORCID: https://orcid.org/0000-0001-8281-4435)
- Daniel Pettersen (ORCID: https://orcid.org/0000-0002-7349-887X)
- Zsolt Cselényi (ORCID: https://orcid.org/0000-0002-8479-6282)
- Magnus Schou (ORCID: https://orcid.org/0000-0002-4314-2418)
- Marcin Ufnal (ORCID: https://orcid.org/0000-0003-0088-8284)
- Aurelija Jučaitė (ORCID: https://orcid.org/0000-0002-2281-6436)
- Macarena P. Quintana‐Hayashi
- Melanie Chan
- Lars H. Lund
- Kathleen Connolly
Institutions
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Stockholm Health Care Services (SE)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Canada) (CA)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1002/ehf2.15412
- Primary Topic
- Pregnancy-related medical research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca